Unleashing the Power of Tregs

Clinical Trials for Neurodegenerative Diseases

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic disease

Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's

About Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). Our multi-modality pipeline includes Treg-enhancing biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy, targeting conditions where dysfunctional Tregs contribute to disease progression.

Our Clinical Programs

Explore our current clinical trial opportunities. Our focus is on generating therapeutics that minimally burden the patient and caregiver while delivering meaningful clinical outcomes.

Our Science

Pioneering the research and development of new therapies to enhance the function of regulatory T cells

COYA 302 for ALS

Treg Enhancing Biologics

Combination therapy currently enrolling patients with Amyotrophic Lateral Sclerosis (ALS)

Currently Enrolling

COYA 302 for FTD

Treg Enhancing Biologics

Combination therapy for Frontotemporal Dementia - FDA IND accepted January 2026

Coming Soon

Participating in Clinical Trials

What to expect when you join one of our research programs

Why Participate?

Access innovative Treg-based treatments, contribute to groundbreaking research, and receive expert care from leading specialists.

Safety First

All trials follow strict FDA-regulated protocols and are reviewed by independent ethics committees to ensure participant safety.

Support Every Step

Our patient advocacy team is with you throughout, answering questions and providing support for you and your caregivers.

Have Questions?

Our team is here to help. Contact us to learn more about our clinical trials and whether you or a loved one may be eligible to participate.

5850 San Felipe St., Suite 500, Houston, TX 77057 USA